clinical trial · NCT04088396
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Eli Lilly and Company·phase3·recruiting·n = 58
Systemic Juvenile Idiopathic ArthritisBaricitinibTocilizumab
brief summary
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.
started
Feb 12, 2020
primary completion
Sep 1, 2026
completion
Sep 1, 2026
last updated
Jul 6, 2026
official title
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol